Back to top
more

Femasys (FEMY)

(Delayed Data from NSDQ)

$0.88 USD

0.88
165,169

-0.05 (-5.33%)

Updated Aug 7, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2,266.67% and -99.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -11.11% and -84.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Femasys (FEMY) delivered earnings and revenue surprises of -35.29% and 77.27%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Curis (CRIS) delivered earnings and revenue surprises of -9.65% and 11.74%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 20.21% and 1.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Femasys (FEMY) delivered earnings and revenue surprises of 8% and 41.80%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Femasys (FEMY) delivered earnings and revenue surprises of -20% and 38.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zealand Pharma AS (ZLDPF) delivered earnings and revenue surprises of 9.68% and 75.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of 21.43% and 17.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device

by Zacks Equity Research

FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.

Zacks Equity Research

Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI

by Zacks Equity Research

FEMY's eco-friendly FemVue MINI receives CE Mark and Health Canada approval, advancing sustainable fallopian tube assessment technology in Europe and Canada.

Zacks Equity Research

Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Femasys (FEMY) delivered earnings and revenue surprises of -16.67% and 55.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omega Therapeutics (OMGA) delivered earnings and revenue surprises of 16.67% and 71.27%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 65.41% and 137.42%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Femasys (FEMY) delivered earnings and revenue surprises of 22.73% and 9.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

IGM Biosciences (IGMS) delivered earnings and revenue surprises of 1.19% and 30.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of 0% and 7.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Femasys (FEMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Femasys (FEMY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Femasys' (FEMY) revenues in third-quarter 2023 are expected to have been driven by the higher international sales of its marketed products. Pipeline updates are expected over the earnings call.

Zacks Equity Research

Bears are Losing Control Over Femasys Inc. (FEMY), Here's Why It's a 'Buy' Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Femasys Inc. (FEMY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Femasys Inc. (FEMY) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Femasys Inc. (FEMY) delivered earnings and revenue surprises of -8.70% and 13.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Voyager Therapeutics (VYGR) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 336.84% and 93.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Femasys Inc. (FEMY) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Femasys Inc. (FEMY) delivered earnings and revenue surprises of 15.38% and 1%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intra-Cellular (ITCI) delivered earnings and revenue surprises of -16.46% and 12.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 32.29% and 3.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?